TRAW, ACRV, GUTS – Three speculative US names to keep on watchlist

TRAW – Traws Pharma ritonavir-free COVID antiviral

Ultra-small biotech trying to turn ratutrelvir into a cleaner, Paxlovid-adjacent oral antiviral, with final Phase 2 data due in January.

*Indicative figures as of 27 Dec 2025, rounded. Data may have moved by the time you read this.

What Traws is actually trying to build

Traws is a clinical-stage antiviral company with a small pipeline, but right now almost the entire story is ratutrelvir: an oral SARS-CoV-2 main protease (3CL/Mpro) inhibitor designed to be used without ritonavir. The goal is simple but ambitious: match Paxlovid’s antiviral punch, while avoiding the drug–drug interaction mess and contraindications driven by ritonavir.

The ongoing study is an open-label, active-controlled Phase 2 in mild-to-moderate COVID-19, with two core components:

• an active comparator cohort vs Paxlovid, focusing on symptom resolution, safety and usability; and
• a separate arm in Paxlovid-ineligible patients, i.e. people with relevant drug–drug interactions or other contraindications where ritonavir-boosted regimens are off the table.

In the pre-specified interim (December 2025), ratutrelvir showed a differentiated profile: fewer adverse events, no viral rebounds and a consistent symptom-improvement signal, including in the ineligible cohort. The dataset is still small and descriptive, but it is enough to justify finishing the 90-patient plan and pushing to a full readout.

Near-term catalyst: final Phase 2 data in January

The company has guided that the final Phase 2 analysis is expected in January 2026. That will include:

• full safety and symptom data for ratutrelvir vs Paxlovid in the randomized cohort;
• a more robust look at outcomes in the Paxlovid-ineligible population;
• first hints at how they might design a potential registrational program (if the numbers justify it).

With barely ~10M in market cap and only about $6.4M in cash as of 30 Sep 2025, this is about as binary as it gets. A clearly positive dataset can re-write the story; a weak or noisy one leaves them with a thin balance sheet and a tired COVID theme.

Why someone might “watch, not rush in”

• Clear narrative if the data are good: a ritonavir-free Paxlovid alternative for high-risk patients who cannot take current regimens, in a world where COVID is now chronic and still dangerous for older, multi-medicated patients.
• Leverage to data: it does not take a huge absolute valuation to move a 10M-cap name if the readout is clearly differentiated and regulators show interest.
• Optionality beyond this trial: success here can also support a broader respiratory antiviral strategy and strengthen their hand in any partnering conversation.

Main risks and red flags

• Balance sheet: with mid-single-digit millions in cash and no obvious revenue stream, a dilutive raise is almost a given if the data are even moderately good.
• COVID fatigue: payers and physicians have seen a wave of COVID products; any new entrant must be clearly better, or at least address a truly underserved corner (such as ineligible patients) to gain traction.
• Study design limitations: open-label, descriptive analysis with a relatively small N leaves plenty of room for bias and over-interpretation.
• Single-asset perception: even though Traws has other programs on paper, right now the market trades it as “the ratutrelvir stock” – all eggs in one viral basket.

Retail chatter snapshot

On the retail side, TRAW has a modest but active presence on platforms like Stocktwits: it is not a meme name, but sentiment clearly spikes around ratutrelvir press releases and Phase 2 headlines. For now it trades more like a pure catalyst vehicle than a steady long-term story; that is exactly why it belongs on a watchlist with a clear plan, not in a portfolio “by inertia”.

ACRV – Acrivon Therapeutics precision oncology / DDR

Small-cap oncology name trying to turn a biomarker-driven CHK1/CHK2 inhibitor into a registrational-grade play in endometrial cancer, with a WEE1/PKMYT1 program right behind it.

*Indicative as of 27 Dec 2025, rounded. Target range from multiple brokers; always check latest figures.

Core thesis: AP3-guided, biomarker-defined oncology

Acrivon’s pitch is that classic histology and basic genomics are not enough to predict who really depends on specific cell-cycle nodes. Their AP3 platform uses functional phosphoproteomics to map which tumors are “wired” to CHK1/CHK2, WEE1/PKMYT1 and related circuitry, and then deploys matching drugs where that wiring is strongest.

The current flagship is ACR-368 (prexasertib), an IV CHK1/CHK2 inhibitor being tested in a registrational-intent Phase 2b trial in endometrial cancer. Only patients who test positive on the OncoSignature assay are included, and this entire package has FDA Fast Track status plus a Breakthrough Device designation for the diagnostic itself. In other words, regulators are open to the “drug + biomarker” concept if the data deliver.

Behind that, ACR-2316 is a dual WEE1/PKMYT1 inhibitor now in Phase 1, targeting tumors where AP3 finds a particularly strong dependency on that arm of the checkpoint machinery. Early data here will be heavy on safety and pharmacodynamics, but any hint of durable responses will be noticed.

Near-term catalyst: January webcast

Acrivon has announced a January 2026 webcast dedicated to:

• updated interim results from the registrational-intent Phase 2b ACR-368 study in endometrial cancer (including the newer biopsy-independent arm);
• initial clinical data from the Phase 1 study of ACR-2316, with safety, dosing and early activity readouts; and
• nomination of a new AP3-derived cell-cycle candidate, including target disclosure.

This is exactly the kind of event where sentiment can flip. Strong CHK1/CHK2 data plus a clean early WEE1/PKMYT1 profile would support the “platform” angle; weak or messy results would reinforce the market’s scepticism about yet another DDR story.

Bulled-up angle: why bulls care

• Biomarker-enriched design: by restricting to OncoSignature-positive tumors, ACR-368 has a better shot at showing meaningful response rates and durability than older, unselected CHK1/2 attempts.
• Regulatory posture already engaged: Fast Track + Breakthrough Device means FDA is at least open to a faster path if data are compelling, especially in a setting with limited options.
• Balance sheet vs valuation: Acrivon still has a multi-year cash runway by its own guidance; pairing that with a sub-100M cap is what attracts “asymmetry” hunters.
• Pipeline depth: ACR-2316 and a third AP3-derived asset give some diversification beyond a single CHK inhibitor.

Bear case in one breath

• Field fatigue: DDR and checkpoint kinase inhibitors have burned a lot of capital in the past decade; the default market stance is sceptical until proven otherwise.
• Clinical risk: Phase 2b is still mid-course and interim; nothing is de-risked until you see mature response and PFS curves, not just response snapshots.
• Competition: other players are also trying to segment endometrial cancer with biomarker-driven approaches; ACR-368 has to be clearly differentiated, not just “another option”.
• Execution on Phase 3: even with good data, designing and running a clean, confirmatory Phase 3 in a niche biomarker-defined population is non-trivial operationally.

Retail chatter snapshot

On retail platforms and message boards, ACRV shows up as a “data-in-January high-beta” name: not meme-tier, but often mentioned in lists of small biotech with outsized analyst price targets versus current levels. The consensus price target cluster around the low-teens while the stock trades in the low single digits, which naturally fuels speculative interest. The key is that, here, sentiment is explicitly data-driven: most traders are waiting to see what the January webcast actually delivers before deciding whether this becomes a serious swing or just another pop-and-fade.

GUTS – Fractyl Health post-GLP-1 obesity / Revita DMR

Metabolic company aiming to own the “what happens after GLP-1” niche, using an endoscopic duodenal resurfacing procedure to keep weight and glycemic control from sliding back.

*Indicative as of 27 Dec 2025, rounded. Analyst ranges from multiple sources; always confirm latest.

Core idea: an “off-ramp” from GLP-1 therapies

GLP-1 drugs like Wegovy and Zepbound have transformed obesity treatment, but they raise a gigantic practical question: what happens when patients stop? Published real-world data suggest substantial weight regain and worsening glycemic control once the injections end, which is a nightmare for both patients and payers.

Fractyl’s answer is Revita, an endoscopic duodenal mucosal resurfacing (DMR) procedure designed to “reset” the duodenal lining and, through that, metabolic signalling. Revita has FDA Breakthrough Device designation specifically for post-GLP-1 weight maintenance, which is exactly the corner of the market they want to own.

In the open-label REVEAL-1 cohort, individuals with obesity who had lost around 24% of their body weight on GLP-1 drugs received a single Revita procedure and then stopped GLP-1. Six months later, they showed only about +1.5% average weight change and nearly flat HbA1c, a stark contrast with published data where GLP-1 discontinuation alone leads to meaningful weight regain and glycemic deterioration.

Near-term catalyst: REMAIN-1 Midpoint randomized data

The key next step is REMAIN-1, a randomized trial in a similar post-GLP-1 population. The so-called Midpoint Cohort (45 participants) has completed enrollment, and Fractyl has guided to six-month randomized data in Q1 / January 2026.

This readout should, for the first time in a controlled setting, quantify how much Revita helps patients maintain weight and metabolic control after stopping GLP-1 compared with a control arm. The company has flagged a potential PMA filing in the second half of 2026 if the dataset is supportive.

Why bulls think this can matter

• Massive unmet “logistical” need: even if GLP-1 drugs remain central, insurers are unlikely to fund life-long injections for everyone. A durable, procedure-based off-ramp is conceptually very attractive.
• Real-world-friendly endpoint: weight maintenance and glycemic stability after GLP-1 withdrawal are straightforward to measure and compelling if the gap vs control is large.
• Regulatory position: Breakthrough Device status and a clear path to PMA make this more than a purely speculative science project.

What can go wrong

• Effect size risk: if Revita’s advantage vs control is modest, enthusiasm can fade quickly; payers and physicians will want a clear delta to justify a procedure.
• Procedural risk and scalability: this is an endoscopic intervention; uptake depends on training, capacity, and how comfortable centres feel performing it at scale.
• Financing and dilution: Fractyl has already tapped the market via share offerings; more capital raises are entirely possible along the pivotal path.
• Competition from pharmacology alone: if next-gen GLP-1 strategies shift toward chronic low-dose maintenance or cheaper generics, the perceived need for a device off-ramp may shrink.

Retail chatter snapshot

GUTS has already had its moment of fame with retail: following positive post-GLP-1 data in 2025, message volume and sentiment on Stocktwits swung into the “extremely bullish” zone, with corresponding spikes in price and volume. Since then, the stock has cooled off into a more neutral range, but it is very clearly on the radar of traders who like high-beta obesity and GLP-1-adjacent names. That means any January randomized data – good or bad – can move the stock hard in either direction.